Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diet and Medication in Cerebrotendinous Xanthomatosis
NCT00004346Phase 2
Key facts
- Status
- Unknown
- Start
- Jan 1996
- Countries
- 1
- Sponsor
- National Center for Research Resources
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Conditions
- cerebrotendinous xanthomatosis (CTX)
01
Overview
Phase 2, open-label trial of lovastatin and chenodeoxycholic acid in cerebrotendinous xanthomatosis (CTX) (2 arms), sponsored by National Center for Research Resources. Primary endpoints: Biosynthesis of cholesterol at 10 weeks, Biosynthesis of cholestanol at 10 weeks and 2 more. Status: unknown.
02
Design
2 arms- Study design
- Non-randomizedOpen-label
Lovastatin Final Arm
Receives Lovastatin in the final phase
CDCA Final Arm
Receives Chenodeoxycholic acid in the final phase
03
Who it enrols
Patients with Cerebrotendinous xanthomatosis.
04
Endpoints
Primary
Biosynthesis of cholesterol
Biosynthesis of cholestanol
Turnover of individual sterols
Turnover of bile acids
Beyond the preview
Go deeper on NCT00004346.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004346.